GLP-2T Explained: The Dual-Agonist Product Code and the Evidence

“GLP-2T” is not the name of a molecule. It is a vendor product code, and reading it correctly matters before anything else. In the grey-market naming convention, the number denotes how many incretin receptors the compound is meant to hit — 1 for a mono-agonist, 2 for a dual agonist, 3 for a triple — and the trailing letter points to a reference drug. So GLP-2T denotes a dual GIP/GLP-1 receptor agonist of the tirzepatide class. That is a description of an intended class, not a guarantee of contents. What the actual compound, dose, and purity are must be confirmed through the product’s Certificate of Analysis (COA); the code alone tells you nothing you can act on safely.

What the tirzepatide class actually does

The science the code borrows from is real and well studied. Tirzepatide is a “twincretin” — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, rather than the single GLP-1 target of drugs like semaglutide. Co-activating both pathways produces a synergistic effect on insulin secretion and appetite that neither hormone matches alone, which is the mechanistic reason dual agonism outperformed the earlier mono-agonist generation.

The dual GIP/GLP-1 mechanism is genuinely established science; a vial sold under a vendor code is not the FDA-approved drug and carries identity, purity, and sterility risk that no mechanism can offset.

The trial evidence

In SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022), 2,539 adults with obesity or overweight were randomized to tirzepatide or placebo for 72 weeks. Mean weight change was dose-dependent:

Treatment	Mean weight change at 72 weeks
Tirzepatide 5 mg	-15.0%
Tirzepatide 10 mg	-19.5%
Tirzepatide 15 mg	-20.9%
Placebo	-3.1%

In type 2 diabetes, the five SURPASS trials (reviewed in Cardiovascular Diabetology, 2022) found tirzepatide 5-15 mg lowered HbA1c by 1.24 to 2.58% and body weight by 5.4-11.7 kg, and it beat the selective GLP-1 agonist semaglutide 1.0 mg on both measures head-to-head.

The trade-off is consistent across the class: the most common adverse events are gastrointestinal — nausea, vomiting, diarrhea, constipation — mostly mild to moderate and concentrated during the dose-escalation period.

Why the code is not the drug

Here is the gap that the science cannot close. The trials above were run on Eli Lilly’s manufactured tirzepatide — the same compound sold as the FDA-approved products Mounjaro and Zepbound. A grey-market “GLP-2T” vial is not that.

Compounded and counterfeit versions are never FDA-approved and do not pass FDA review for safety, purity, or manufacturing quality. Regulators and the manufacturer have documented products marketed as tirzepatide that contained bacteria, high impurity levels, the wrong color, a completely different chemical structure, or in one case only sugar alcohol. Multiple sterility-failure recalls have removed thousands of vials from the market. Applying trial statistics to an unverified vial assumes the vial contains what the trials tested — an assumption a COA can support but a product code cannot.

The takeaway

The dual GIP/GLP-1 mechanism behind the “GLP-2T” code is backed by strong human trial data: roughly 20.9% average weight loss at the top dose over 72 weeks and clear glycemic superiority over a leading mono-agonist. But that evidence describes a specific, regulated drug — not whatever a vendor ships under a class code. Treat the science as real and the product as unverified until a COA confirms identity, dose, and purity. Those are two different confidence levels, and conflating them is the actual risk here.

Sources

• Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022
• Nauck & D’Alessio, Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for type 2 diabetes, Cardiovascular Diabetology, 2022
• Eli Lilly, The risks of counterfeit and compounded medicine